^
Association details:
| Biomarker: | Chr del(7q) |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy
Published date:
11/04/2020
Excerpt:
Only 10.5% (2/19) patients with deletion 7/7q achieved a CR/CRI to azacitidine/nivolumab compared with 36.8% (14/38) of patients without the deletion (p=0.03) (Fig 1D)...To decouple azacitidine from nivolumab effect, we evaluated an independent cohort of R/R AML (n=99) treated on azacitidine-based studies without immune checkpoint blockade (ICB) and found no such correlation, suggesting that deletion 7/7q induced resistance may be primarily in PD-1 blockade therapy setting...
Secondary therapy:
azacitidine
DOI:
https://doi.org/10.1182/blood-2020-137335
Trial ID:
